FDAnews Drug Daily Bulletin

Celator Pharmaceuticals, the Leukemia & Lymphoma Society Announce Positive Data from Phase IIb Study of CPX-351

Dec. 13, 2011
A A
Celator Pharmaceuticals announced positive clinical data in first relapse patients with acute myeloid leukemia treated with CPX-351 (cytarabine:Daunorubicin) Liposome Injection.
MarketWatch